Mizuho raised the firm’s price target on Amylyx (AMLX) to $16 from $12 and keeps an Outperform rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx Pharmaceuticals Advances Phase 3 Study for Post-Bariatric Hypoglycemia Treatment
- Amylyx Pharmaceuticals Advances ALS Treatment with Promising Study Update
- Amylyx price target raised to $20 from $12 at Citi
- Amylyx price target raised to $19 from $10 at Baird
- Amylyx price target raised to $16 from $14 at BofA